(24/7 MARKET NEWS) – PDS Biotechnology Corporation (Nasdaq: PDSB) announced, this morning, the results of a Phase II trial studying the combination of PDS0101 with standard-of-care chemoradiotherapy. Highlights include 9 out of 9 (100%) participant showed clinical response (>60% tumor shrinkage at mid-point evaluation) and 8 out of 9 (89%) had no evidence of disease (complete response) on day 170
Versus is trading in this morning’s premarket at $5.75 +0.15 (+2.68%) 304,317 shares.
Its 52-week range is $2.89 to $11.57, with its next inflection points at $5.90 and $6.00. If it can break through the $6 level, on strong volume, it may try to make a run for the $7 level, which it hasn’t seen since March.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
